nab-paclitaxel + durvalumab

nab-paclitaxel + durvalumab is an investigational combination therapy of **nab-paclitaxel**, a cremophor-free albumin-bound formulation of paclitaxel (a taxane chemotherapy), and **durvalumab**, a monoclonal antibody immune checkpoint inhibitor targeting PD-L1. nab-paclitaxel disrupts microtubule function, thereby inhibiting cell division, while durvalumab blocks the interaction of PD-L1 with PD-1 and CD80, enhancing antitumor immune responses. This combination has been studied primarily in advanced non-small cell lung cancer (NSCLC) after failure of initial platinum-based therapy and, investigationally, in other cancers including pancreatic adenocarcinoma. The regimen aims to leverage both cytotoxic and immunomodulatory mechanisms; it has demonstrated feasibility and antitumor activity with no unexpected safety signals in clinical studies[1][3][5].

Brand names

Abraxane (nab-paclitaxel)Imfinzi (durvalumab)

Other names

nab-paclitaxel plus durvalumab